Scholar Rock Holding Corp. Stock News

Investors continue to search for the next big weight loss drug stocks following the success of Eli Lilly (NYSE: LLY ) and Novo Nordisk (NYSE: NVO ). So-called GLP-1 receptor agonists represent a funda

Scholar Rock's stock price has increased from $6 to $16, indicating increased market interest. Scholar Rock develops apitegromab, a targeted therapy for Spinal Muscular Atrophy (SMA) that inhibits myo

Americans live longer than ever, and a handful of biotech stocks stand at the forefront of longevity's future. Many misconceive anti-aging stocks as peddling some magic pill that inexplicably makes yo

Scholar Rock Holding Corporation (NASDAQ:SRRK ) Q3 2023 Earnings Conference Call November 7, 2023 8:00 AM ET Company Participants Rushmie Nofsinger - Vice President, Investor Relations & Corporate Aff

The average of price targets set by Wall Street analysts indicates a potential upside of 99.1% in Scholar Rock Holding Corporation (SRRK). While the effectiveness of this highly sought-after metric is

If you are looking for stocks that are well positioned to maintain their recent uptrend, Scholar Rock Holding Corporation (SRRK) could be a great choice. It is one of the several stocks that passed th

The Scholar Rock Holding Corporation phase 3 SAPPHIRE study for apitegromab for the treatment of type 2 and type 2 SMA patients has completed enrollment and is expected to report results in Q4 2024. D

Scholar Rock Holding Corporation (SRRK) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the

Scholar Rock (SRRK) rises on plans to advance SRK-439 for treating obesity and offering common stock.

Scholar Rock announced it will advance the development of its obesity treatment, SRK-439, starting with a phase 2 proof-of concept trial in 2024. The biopharma company will work toward an investigatio

Tap four stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include AMC Entertainment (AMC), Scholar Rock (SRRK), PTK Acquisition (VLN), OI Glass (OI) and Sera Progn

Scholar Rock Holding Corp. is developing a growth factor targeted therapy called apitegromab for Spinal Muscular Atrophy. Positive interim data from a phase 2 trial showed sustained improvement in mot

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a f

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a f